Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFIRINOX for First-line Treatment of Advanced Urachus Cancer
KCT0005551Phase 2Not yet recruiting
- Sponsor
- GC Biopharma
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX, sponsored by GC Biopharma. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
FOLFIRINOX
Beyond the preview
Go deeper on KCT0005551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005551.